Cough and respiratory problems in COVID-19 pandemic context: the place of mucoactive therapy

The combination of acetyl cysteine and ambroxol (PulmoBREATHE®, MoviHealth) is pathogenetically justified, since it restores the components of mucociliary clearance due to the complementarity and synergy of the main and pleiotropic effects, which ensures overcoming of inflammation and intoxication in acute respiratory infections.

Often, when treating a viral-bacterial infection, it becomes necessary to increase the permeability of antibiotics and enhance their activity by destroying biofilms and inhibiting their formation. For this, Movinaza® (MoviHealth) medicine is prescribed.